MaxCyte Operating Margin from 2010 to 2026
| MXCT Stock | USD 0.74 0.01 1.19% |
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.8 M, Interest Expense of 138.6 K or Selling General Administrative of 35.9 M, as well as many indicators such as Price To Sales Ratio of 12.34, Dividend Yield of 0.0 or PTB Ratio of 2.0. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
MaxCyte | Operating Margin | Build AI portfolio with MaxCyte Stock |
The evolution of Operating Margin for MaxCyte provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how MaxCyte compares to historical norms and industry peers.
Latest MaxCyte's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of MaxCyte over the last few years. It is MaxCyte's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.62) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
MaxCyte Operating Margin Regression Statistics
| Arithmetic Mean | (0.62) | |
| Coefficient Of Variation | (74.48) | |
| Mean Deviation | 0.36 | |
| Median | (0.51) | |
| Standard Deviation | 0.46 | |
| Sample Variance | 0.21 | |
| Range | 1.4381 | |
| R-Value | (0.82) | |
| Mean Square Error | 0.07 | |
| R-Squared | 0.68 | |
| Significance | 0.000049 | |
| Slope | (0.08) | |
| Total Sum of Squares | 3.42 |
MaxCyte Operating Margin History
About MaxCyte Financial Statements
MaxCyte shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. Maxcyte operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.